Tags : Lyra Therapeutics


Lyra Therapeutics (Formally 480 Biomedicals) Developing Innovative Therapeutics for ENT

Shots: This round is led by Perceptive Advisors, RA Capital Management, ArrowMark Partners & Soleus Capital, along with existing investors Polaris Venture Partners, North Bridge Venture Partners & Intersouth Partners Funding will be utilized to plan P-II for LYR-210 in Chronic rhinosinusitis (CRS) Lyra is using its proprietary transmucosal platform for developing treatment for various […]Read More